Parkinson’s Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Development analyses DelveInsight.
Parkinson’s Disease Overview
Parkinson’s disease is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called the substantia nigra.
“Parkinson’s Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.
The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Parkinson’s Disease Pipeline Report
- Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years. Parkinson’s Disease Key players such as – Cantabio Pharmaceuticals, Treefrog Therapeutics, Nobilis Therapeutics, AstraZeneca, Lundbeck A/S, Kissei Pharmaceutical, Roche, Pharma Two B, Denali Therapeutics Inc., Cerevel Therapeutics, and others, are developing therapies for the Parkinson’s Disease treatment
- Parkinson’s Disease Emerging therapies such as – CB101, Neural microtissues, NBTX 001, MEDI1341, Lu AF28996, KDT 3594, Prasinezumab, P2B001, DNL 151, Tavapadon, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.
- In February 2021, Cerevel Therapeutics initiated a 58-Week Open-label Trial of Tavapadon in Parkinson’s Disease. The purpose of this study is to evaluate the safety and efficacy of long-term administration offlexible doses of tavapadon in participants with Parkinson’s Disease.
Parkinson’s Disease Pipeline Therapeutics Assessment
- Parkinson’s Disease Assessment by Product Type
- Parkinson’s Disease By Stage and Product Type
- Parkinson’s Disease Assessment by Route of Administration
- Parkinson’s Disease By Stage and Route of Administration
- Parkinson’s Disease Assessment by Molecule Type
- Parkinson’s Disease by Stage and Molecule Type
DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:
- CB101: Cantabio Pharmaceuticals
- Neural microtissues: Treefrog Therapeutics
- NBTX 001: Nobilis Therapeutics
- MEDI1341: AstraZeneca
- Lu AF28996: Lundbeck A/S
- KDT 3594: Kissei Pharmaceutical
- Prasinezumab: Roche
- P2B001: Pharma Two B
- DNL 151: Denali Therapeutics Inc.
- Tavapadon: Cerevel Therapeutics
Parkinson’s Disease Pipeline Analysis:
The Parkinson’s Disease pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the Parkinson’s Disease treatment with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
- Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies
Parkinson’s Disease Pipeline Market Drivers
- Increasing prevalence of Parkinson’s Disease patients
- Robust clinical-stage pipeline
Parkinson’s Disease Pipeline Market Barriers
- Lack of awareness and delayed diagnosis
- Side effects associated with Parkinson’s disease treatment drugs
Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Assessment
Scope of Parkinson’s Disease Pipeline Drug Insight
- Coverage: Global
- Key Parkinson’s Disease Companies: Cantabio Pharmaceuticals, Treefrog Therapeutics, Nobilis Therapeutics, AstraZeneca, Lundbeck A/S, Kissei Pharmaceutical, Roche, Pharma Two B, Denali Therapeutics Inc., Cerevel Therapeutics, and others
- Key Parkinson’s Disease Therapies: CB101, Neural microtissues, NBTX 001, MEDI1341, Lu AF28996, KDT 3594, Prasinezumab, P2B001, DNL 151, Tavapadon, and others
- Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies
- Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers
Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials
Table of Contents
|1||Parkinson’s Disease Report Introduction|
|2||Parkinson’s Disease Executive Summary|
|3||Parkinson’s Disease Overview|
|4||Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment|
|5||Parkinson’s Disease Pipeline Therapeutics|
|6||Parkinson’s Disease Late Stage Products (Phase II/III)|
|7||Parkinson’s Disease Mid Stage Products (Phase II)|
|8||Parkinson’s Disease Early Stage Products (Phase I)|
|9||Parkinson’s Disease Preclinical Stage Products|
|10||Parkinson’s Disease Therapeutics Assessment|
|11||Parkinson’s Disease Inactive Products|
|12||Company-University Collaborations (Licensing/Partnering) Analysis|
|13||Parkinson’s Disease Key Companies|
|14||Parkinson’s Disease Key Products|
|15||Parkinson’s Disease Unmet Needs|
|16||Parkinson’s Disease Market Drivers and Barriers|
|17||Parkinson’s Disease Future Perspectives and Conclusion|
|18||Parkinson’s Disease Analyst Views|
Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies
Parkinson’s Disease Market
DelveInsight’s ‘Parkinson’s Disease-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Parkinson’s Disease Epidemiology
DelveInsight’s ‘Parkinson’s Disease Epidemiology Forecast to 2032‘ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Recent Blogs By DelveInsight:
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.